14
Table 7 . Combination with second-generation immune checkpoint inhibitors
FIRST-GENERATION IMMUNE CHECKPOINT INHIBITOR
SECOND-GENERATION IMMUNE CHECKPOINT INHIBITOR
CONDITION
PHASE I |
NCT01714739 |
Nivolumab / Opdivo |
Lirilumab ( anti-KIR ) |
Metastatic and / or unresectable |
|
|
|
|
solid tumors |
PHASE I / 1B
PHASE I / II
NCT01968109
NCT02658981
NCT02179918
Pembrolizumab / MK- 3475 / Keytruda
BMS-986016 ( anti- LAG-3 )
BMS 986016 ( anti- LAG-3 ) or urelumab ( anti-4-1BB )
PF-05082566 ( anti-4- 1BB )
Advanced metastatic and / or unresectable solid tumors
Recurrent glioblastoma , gliosarcoma , recurrent brain neoplasm
Advanced solid tumors
NCT02676869 |
IMP321 ( anti-LAG-3 ) |
Unresectable or metastatic stage |
|
|
III / IV melanoma |
NCT02553499 MK-1248 ( anti-GITR ) Advanced solid tumors
NCT02304393 Atezolizumab / MPDL3280A
RO7009789 ( anti- CD40 )
Metastatic or advanced solid tumors
NCT02655822 |
CPI-444 |
NSCLC , malignant melanoma , renal cell cancer , TNBC , prostate cancer , head and neck cancer , colorectal cancer , bladder cancer |
NCT01103635 |
Tremelimumab |
CP-870,893 ( anti- |
|
|
CD40 ) |
NCT02705482 Durvalumab / MEDI4736 or tremelimumab
NCT02221960 Durvalumab / MEDI4736
NCT02655822 Atezolizumab / MPDL3280A
MEDI0562 ( anti-OX40 )
MEDI6383 ( anti-OX40 )
Recurrent or stage IV melanoma
Select advanced solid tumors
Recurrent or metastatic solid tumors
CPI-444 ( anti-aA2A ) NSCLC , malignant melanoma , renal cell cancer , TNBC , prostate cancer , head and neck cancer , colorectal cancer , bladder cancer
NCT02460224 PDR001 * LAG525 ( anti-LAG-3 ) Advanced solid tumors
NCT02608268 MBG453 ( anti-TIM-3 ) Advanced solid tumors
NCT02253992 |
Nivolumab / Opdivo |
Urelumab ( anti-4-1BB ) |
Advanced solid tumors , |
|
|
|
advanced B-cell non-Hodgkin ’ s |
|
|
|
lymphoma ( NHL ) |
NCT02335918 |
Varlilumab ( anti-CD27 ) |
NSCLC , melanoma , ovarian |
|
|
cancer , colon cancer |
NCT02543645 |
Atezolizumab |
Varlilumab ( anti-CD27 ) |
Renal cell carcinoma , urogenital cancer , melanoma , TNBC , bladder cancer , head and neck cancer , NSCLC |
NCT02554812 |
Avelumab |
PF-05082566 ( anti-4- |
|
|
1BB ) |
NCT02205333
Tremelimumab or durvalumab / MEDI4736
Advanced solid tumors
MEDI6469 ( anti-OX40 ) Advanced solid tumors , aggressive B-cell lymphomas
NCT02413827 |
Ipilimumab / Yervoy |
Varlilumab ( anti-CD27 ) Unresectable Stage III or IV |
|
|
melanoma |
OTHER THERAPIES
Rituximab ( anti-CD-20 )
CDX-1401 ( vaccine ), poly- ICLC ( adjuvant )
PILOT |
NCT02652455 |
Nivolumab / Opdivo |
CD137 |
Melanoma |
Surgery , chemotherapy , TIL infusion , IL-2 |
* ANTI-PD-1